

FIG. 1



T_α = 1.42 days
T_β = 22.0 days
CL = 2.54 mL/day/kg
V_c = 41.3 mL/kg
F_{alpha} = 0.061

LOQ = Limit of Quantification

FIG. 2



T_α = 1.6 days
T_β = 22.7 days
CL = 2.4 mL/day/kg
V_c = 40.7 mL/kg
F_{alpha} = 0.068

LOQ = Limit of Quantification

FIG. 3



0
-10
-20
-30
-40
-50
Change from Baseline (%)
Placebo
0.01
0.03
0.1
0.3
1.0
Treatment Groups (mg/kg)

FIG. 4



Change in LVEDD(%)
60
50
40
30
20
10
AMI surgery
Baseline
1 week
2 weeks
4 weeks
Treatment
Saline solution
Control IgG
mAb 0.05 mg/kg
mAb 0.5 mg/kg
mAb 5.0 mg/kg
* P<0.05 vs controls (IgG and saline)
Change in LVESD(%)
120
100
80
60
40
20
AMI surgery
Baseline
1 week
2 weeks
4 weeks
Treatment
Saline solution
Control IgG
mAb 0.05 mg/kg
mAb 0.5 mg/kg
mAb 5.0 mg/kg
* P<0.05 vs controls (IgG and saline)
Change in LVFS(%)
0
-20
-40
-60
-80
AMI surgery
Baseline
1 week
2 weeks
4 weeks
Treatment
Saline solution
Control IgG
mAb 0.05 mg/kg
mAb 0.5 mg/kg
mAb 5.0 mg/kg
* P<0.05 vs controls (IgG and saline)

FIG. 5



Akinetic segments
5
4
3
2
1
*
AMI
AWDT (MM)
1.0
0.8
0.6
0.4
0.2
*
AMI
Sham-operated
Saline solution
Control IgG
mAb 0.05 mg/kg
mAb 0.5 mg/kg
mAb 5.0 mg/kg
* P<0.05 vs all AMI-groups
Myocardial performance index
0.5
0.4
0.3
0.2
0.1
*
**
**
**
AMI
TAPSE (mm)
1.2
1.0
0.8
0.6
0.4
0.2
*
**
**
AMI
Sham-operated
Saline solution
Control IgG
mAb 0.05 mg/kg
mAb 0.5 mg/kg
mAb 5.0 mg/kg
* P<0.05 vs all AMI-groups
** P<0.05 vs controls (IgG and saline)

FIG. 6



rhIL-1β
Macrophage co-culture
IL-6
[IL-6] ng/ml
IL-8
[IL-8] µg/ml
[IL-8] ng/ml
MCP-1
[MCP-1] ng/ml
PAI-1
[PAI-1] ng/ml
*=p<0.05 vs. stimulated (2-tailed t test)
**=p<0.001 vs. stimulated (2-tailed t test)
HUVEC + + +
rhIL-1β - + +
XOMA 052 - - +
Control cells + - - - -
HUVEC/Mϕ's + + + +
XOMA 052 - - + ++ +++

FIG. 7



rhIL-1β
Macrophage co-culture
MMP-3
BQL
[MMP-3] ng/ml
20
15
10
5
0
**
**
MMP-9
BQL
[MMP-9] ng/ml
300
225
150
75
0
*
*
*
IL-6
[IL-6] pg/ml
3000
2500
2000
1500
1000
500
0
**
[IL-6] pg/ml
3000
2500
2000
1500
1000
500
0
*
*
*
IL-8
[IL-8] ng/ml
120
100
80
60
40
20
0
**
[IL-8] ng/ml
750
600
450
300
150
0
*
*=p<0.05 vs. stimulated (2-tailed t test)
**=p<0.001 vs. stimulated (2-tailed t test)
CASMC + + +
rhIL-1β - + +
XOMA 052 - - +
Control cells + - - - -
CASMC/Mϕ's + + + + +
XOMA 052 - - + ++ +++

FIG. 8A



Average lesion area
30
20
10
0
% Sudan IV
***
***
*
**
66%
37%
22%
29%
0%
Vehicle
Quinapril
XMA 052 MG1K 0.1 mg/kg
XMA 052 MG1K 1.0 mg/kg
XMA 052 MG1K 10 mg/kg
antibody control
Group
* = p≤0.05
** = p≤0.01
*** = p≤0.001
% = % inhibition

FIG. 8B




Lesion area: Individuals
40
30
20
10
0
% Sudan IV
Vehicle
Quinapril
XMA 052 MG1K 0.1 mg/kg
XMA 052 MG1K 1.0 mg/kg
XMA 052 MG1K 10 mg/kg
antibody control
Group

FIG. 9


Plaque lesions: Representative individuals
Vehicle
Quinapril
0.1 mg/kg XMA052 MG1K
1.0 mg/kg XMA052 MG1K
10 mg/kg XMA052 MG1K
Control antibody
In
Out
3
58
38
11
46
55